CV Effects of Diabetes Medications: Lessons learned from Cardiovascular Outcomes Trials

Reducing cardiovascular risk in type 2 diabetes by glucose lowering – does the drug matter?Подробнее

Darren K. McGuire | Antihyperglycemic Medications for Cardiovascular Risk ReductionПодробнее

GLP1 RA and Cardiovascular Outcome Trials | IDEC2021Подробнее

Recent and Upcoming Diabetes Outcome TrialsПодробнее

Dr. Sanjay KalraПодробнее

CV Outcomes Studies With Medications Indicated for DiabetesПодробнее

Protocols for Safe Use of SGLT2i and GLP1RA in the Hospital SettingПодробнее

Cardiovascular Disease Burden in Type 2 Diabetes: Strategies to Improve OutcomesПодробнее

James R. Gavin III, MD, PhDПодробнее

Type 2 Diabetes: New Guidelines and ControversiesПодробнее

Professor David Wheeler - 'How do SGLT2 inhibitors benefit the kidney?'Подробнее

Professor Stephen Wiviott - 'SGLT2 Outcome trials - an evolving story'Подробнее

State of the Art: Diabetes Management with Respect to CVD and CKD in 2018Подробнее

Darren McGuire | Cardiovascular effects of diabetes medications: Lessons learned from CVOTsПодробнее

Journal Club- June 2018: Semaglutide and CV OutcomesПодробнее

DRF 19: Cardiovascular Outcomes for Diabetes Drugs: Lessons Learned and Path ForwardПодробнее

Cardiovascular Outcomes with Antidiabetic AgentsПодробнее

A Historic View on CV Outcomes in DiabetesПодробнее

Treatment of Diabetes- Update and Physiologic Approach 3/29/17Подробнее